Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen-sensitized dendritic cell vaccine (Sichuan University)
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- Vaccines & Immunotherapeutics, Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
This personalized immunotherapy, developed by Sichuan University, is a combination of an autologous dendritic cell (DC) vaccine and sensitized T cells designed to treat advanced solid tumors, including melanoma, bladder cancer, and colorectal cancer. The process involves identifying patient-specific mutations (neoantigens) through genomic sequencing of the tumor. Autologous dendritic cells are then loaded with these neoantigens *ex vivo* to create a vaccine that, when administered subcutaneously, primes the patient's immune system. This is supplemented by the administration of T cells that have been sensitized to the same neoantigens to enhance the anti-tumor response. The therapy aims to provide a highly specific immune attack against the patient's unique tumor profile while minimizing off-target effects.
- Other names
- Neoantigen-sensitized DC vaccinePersonalized Neoantigen DC Vaccine and T-cell TherapyTumor antigen-sensitized DC vaccine and their sensitized T cells
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Personalized neoantigen-sensitized dendritic cell vaccine (Sichuan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen-sensitized dendritic cell vaccine (Sichuan University).